Acorda Submits New Drug Application to U.S. Food and Drug Administration for CVT-301


(July 7, 2017) - Acorda Therapeutics, Inc.has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for INBRIJATM (CVT-301, levodopa inhalation powder). Acorda is developing INBRIJA as a treatment for symptoms of OFF periods in people with Parkinson’s taking a carbidopa / levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms. The trade name for CVT-301, INBRIJA, has been conditionally accepted by the FDA. Read more

Click for a printer friendly version

Back to top